Trials / Unknown
UnknownNCT05020639
A Study of TQB3820 in Patients With Hematological Malignancies
A Phase I Study to Evaluate the Tolerability and Pharmacokinetics of TQB3820 in Relapsed or Refractory Multiple Myeloma (R/R MM) or Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (R/R B-NHL)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct multiple aspects of the immune dysregulation mediated by B cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3820 tablets | TQB3820 is a novel cereblon-modulating agent. |
Timeline
- Start date
- 2021-08-31
- Primary completion
- 2024-08-01
- Completion
- 2024-12-31
- First posted
- 2021-08-25
- Last updated
- 2021-09-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05020639. Inclusion in this directory is not an endorsement.